NYSEAMERICAN:IBIO iBio (IBIO) Stock Price, News & Analysis → He Is Giving Away Bitcoin (From Crypto Swap Profits) (Ad) Free IBIO Stock Alerts $1.77 -0.12 (-6.35%) (As of 04/18/2024 ET) Add Compare Share Share Today's Range$1.73▼$1.9050-Day Range N/A52-Week Range$1.02▼$28.20Volume179,744 shsAverage Volume3.23 million shsMarket Capitalization$6.16 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsShort InterestStock AnalysisChartEarningsShort Interest Get iBio alerts: Email Address Ad Crypto Swap ProfitsHe Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here About iBioiBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.Read More IBIO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IBIO Stock News HeadlinesApril 11, 2024 | americanbankingnews.comShort Interest in iBio, Inc. (NYSEAMERICAN:IBIO) Increases By 172.7%March 27, 2024 | msn.comUS Futures Trend Higher Wednesday Pre-Bell as Investors Eye Impending Economic, Inflation Data ReadingsApril 19, 2024 | Crypto Swap Profits (Ad)He Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.March 27, 2024 | markets.businessinsider.comIBio In Partnership With AstralBio; Shares Up In Pre-marketSee More Headlines Receive IBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iBio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/09/2024Today4/18/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNYSEAMERICAN:IBIO CUSIPN/A CIKN/A Webwww.ibioinc.com Phone302-355-0650Fax302-356-1173Employees26Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-65,010,000.00 Net MarginsN/A Pretax Margin-41,546.00% Return on Equity-150.59% Return on Assets-52.83% Debt Debt-to-Equity Ratio0.04 Current Ratio0.91 Quick Ratio0.91 Sales & Book Value Annual Sales$2.38 million Price / Sales2.59 Cash FlowN/A Price / Cash FlowN/A Book Value$15.15 per share Price / Book0.12Miscellaneous Outstanding Shares3,480,000Free Float3,445,000Market Cap$6.16 million OptionableN/A Beta-3.77 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Martin B. Brenner D.V.M. (Age 53)Ph.D., CEO & Chief Scientific Officer Comp: $577.31kMr. Felipe Duran (Age 44)Chief Financial Officer Comp: $1.07MStephen KilmerInvestor Relations OfficerMr. Marc Banjak J.D.General CounselMr. Robert B. Kay (Age 84)Interim Secretary & Interim Treasurer Comp: $92.69kKey CompetitorsUniverse PharmaceuticalsNYSE:UPCSunshine BiopharmaNASDAQ:SBFMGraybug VisionNASDAQ:GRAYEnveric BiosciencesNASDAQ:ENVBShuttle PharmaceuticalsNASDAQ:SHPHView All CompetitorsInstitutional OwnershipCitadel Advisors LLCSold 90 shares on 2/15/2024Ownership: 0.000%Simplex Trading LLCSold 300 shares on 2/2/2024Ownership: 0.000%View All Institutional Transactions IBIO Stock Analysis - Frequently Asked Questions Are investors shorting iBio? iBio saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 161,700 shares, an increase of 172.7% from the March 15th total of 59,300 shares. Based on an average trading volume of 3,680,000 shares, the days-to-cover ratio is currently 0.0 days. Approximately 1.9% of the company's shares are sold short. View iBio's Short Interest. How were iBio's earnings last quarter? iBio, Inc. (NYSEAMERICAN:IBIO) released its earnings results on Friday, February, 9th. The company reported ($2.42) earnings per share (EPS) for the quarter. What other stocks do shareholders of iBio own? Based on aggregate information from My MarketBeat watchlists, some companies that other iBio investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Heat Biologics (HTBX), Novavax (NVAX), Dynavax Technologies (DVAX), Co-Diagnostics (CODX), Nokia Oyj (NOK) and Moderna (MRNA). How do I buy shares of iBio? Shares of IBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEAMERICAN:IBIO) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingBiden’s $374B Giveaway Into This SectorDTIForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHe Is Giving Away BitcoinCrypto Swap ProfitsUrgent alert: open this for a huge profit potentialTimothy SykesThe #1 Crypto for 2024InvestorPlaceHow Biden has already won 2024Porter & CompanyOptions trading has suddenly become more reliable.Eagle Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.